March 31, 2025 12:23 PM EDTUpdated 02:06 PM

Merck’s PAH drug cuts risk of serious events by 76% in trial stopped for efficacy

Elizabeth Cairns

Senior biopharma journalist

New data unveiled Monday showed that Merck’s Winrevair can significantly cut the risk of death, lung transplantation and hospitalization in patients …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck’s PAH drug cuts risk of serious events by 76% in trial stopped for efficacy

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Firings sweep across FDA as former leaders lament the gutting of drug agency

RFK Jr. has long criticized drug ads. He just slashed the FDA office that regulates them

‘It’ll be a challenge’: BIO chief Crowley addresses seismic FDA overhaul

Sanofi continues its bet on R&D by poaching GSK’s head of development

Big ambitions at Merck and AstraZeneca — along with a few giant pitfalls — reshape top ranks of the R&D 15

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO

Mer­ck’s PAH drug cuts risk of se­ri­ous events by 76% in tri­al stopped for ef­fi­ca­cy

Senior biopharma journalist

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Merck’s PAH drug cuts risk of serious events by 76% in trial stopped for efficacy